» Articles » PMID: 36462498

SKA1 Promotes Tumor Metastasis Via SAFB-mediated Transcription Repression of DUSP6 in Clear Cell Renal Cell Carcinoma

Overview
Specialty Geriatrics
Date 2022 Dec 3
PMID 36462498
Authors
Affiliations
Soon will be listed here.
Abstract

The most hostile form of urologic cancer, clear cell renal cell carcinoma (ccRCC), has a high fatality rate and poor prognosis due to tumor metastasis at initial presentation. The complex process driving ccRCC metastasis is still unknown, though. In this study, we demonstrate that Spindle and kinetochore-associated protein 1 (SKA1) expression is significantly upregulated in ccRCC tissues and associated with aggressive clinicopathologic characteristics. Functionally, SKA1 knockdown on ccRCC cells reduced cancer cell motility both and research. These bioactivities of SKA1 may be brought on by its specific interaction with scaffold attachment factor B, according to the proposed mechanism (SAFB), which could further depress the transcription of dual specificity phosphatase 6 (DUSP6). Our findings may provide a new way of researching SKA1-regulated tumor metastasis, and indicate that SKA1 is a prospective therapeutic target for renal carcinoma.

References
1.
Jeyaprakash A, Santamaria A, Jayachandran U, Chan Y, Benda C, Nigg E . Structural and functional organization of the Ska complex, a key component of the kinetochore-microtubule interface. Mol Cell. 2012; 46(3):274-86. DOI: 10.1016/j.molcel.2012.03.005. View

2.
Yu W, Min D, Lin F, Zheng S, Tang L, He A . SKA1 induces de novo MTX-resistance in osteosarcoma through inhibiting FPGS transcription. FEBS J. 2019; 286(12):2399-2414. DOI: 10.1111/febs.14808. View

3.
Colas E, Pedrola N, Devis L, Ertekin T, Campoy I, Martinez E . The EMT signaling pathways in endometrial carcinoma. Clin Transl Oncol. 2012; 14(10):715-20. DOI: 10.1007/s12094-012-0866-3. View

4.
Suo L, Chang X, Xu N, Ji H . The Anti-proliferative Activity of GnRH Through Downregulation of the Akt/ERK Pathways in Pancreatic Cancer. Front Endocrinol (Lausanne). 2019; 10:370. PMC: 6590102. DOI: 10.3389/fendo.2019.00370. View

5.
Rassy E, Flippot R, Albiges L . Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol. 2020; 12:1758835920907504. PMC: 7081462. DOI: 10.1177/1758835920907504. View